Navigation Links
Kinexus Announces the Launch of New Peptide Production Services
Date:3/16/2010

New Peptide Array Facility Designed to Expedite the Drug Discovery Process

VANCOUVER, March 16 /PRNewswire/ - Kinexus Bioinformatics Corporation, a world leader in functional proteomics research, announced the launch of a new peptide synthesis facility to provide researchers with the latest in peptide array technologies. These new services will facilitate and expedite access to peptide platforms for innovative approaches to proteomic research and discovery. A variety of peptide services are being made available by Kinexus to the research community including:

    -   Protein Labeling,
    -   Screening of peptide arrays like Epitope Mapping, Substitution
        Analysis, and Peptide Library Screening,
    -   Custom Peptide Synthesis including modified peptides like
        phosphopeptides, histones, cyclized and labeled peptides,
    -   CelluSpots(TM) Custom Peptide Arrays on Glass Slides, and
    -   CelluSpots(TM) Kinase Substrate Peptide Arrays on Glass Slides.

"Kinexus' peptide-based products strongly complement our existing portfolio of cell signaling, proteomics and bioinformatics services," stated Dr. Steven Pelech, president and Chief Scientific Officer of Kinexus Bioinformatics Corporation. "These new products will give Kinexus customers access to high-throughput peptide synthesis and screening platforms, which will accelerate research in the field of signal transduction. The Peptide Array Facility is the latest addition to a unique integrated suite of proteomics services offered by Kinexus which delivers solutions and services for pharmaceutical, biotechnology, academic, life science, clinical and government research laboratories from around the world.

To learn more about the new Peptide Production Services or any of the other proteomics services available, please visit www.kinexus.ca. Kinexus Bioinformatics Corporation is a privately held, biotechnology company engaged in the research and development of innovative methods to understand the relationships of signaling proteins in molecular communication networks. The application of this knowledge positions Kinexus and its clients in drug development, rational drug design, disease diagnosis and personalized therapies to improve human health.

SOURCE Kinexus Bioinformatics Corporation

Back to top
'/>"/>
SOURCE Kinexus Bioinformatics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Kinexus Announces the Launch of a New Protein Kinase Microarray
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. (OTCQB: ... focused on developing and commercializing products to treat rare ... today that it will be hosting an Investor Webcast ... on the origins of innate defense regulators (IDRs) as ... of oral mucositis and the recently announced and published ...
(Date:12/8/2016)... Dec. 8, 2016 Eutilex Co. Ltd. today ... (US $18.9M) Series A financing. This financing round included ... Venture and SNU Bio Angel. This new funding brings ... KRW (US $27.7M) since its founding in 2015. ... the development and commercialization of its immuno-oncology programs, expand ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... its phase I/II dose escalation and expansion clinical trial for its lead drug ... Austria. The purpose of the trial was to determine the safety, antitumor activity, ...
(Date:12/7/2016)... 2016 Neogen Corporation (NASDAQ: NEOG ... Kephart as its chief science officer — a ... responsibilities at Neogen effective Jan. 1. Kephart ... agribusiness unit of Thermo Fisher Scientific, as well as ... His extensive industry experience also includes the management of ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
(Date:12/6/2016)... DALLAS , Dec. 6, 2016 ... criminal justice technology solutions for public safety, investigation, ... (PEP) jointly announced today a five (5) year ... exclusive agreement to expand the rehabilitation and reentry ... PEP History Established in 2004, the Prison ...
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):